National Institute of Allergy and Infectious Diseases, U.S. Public Health Service, Dept of Health and Human Services, United States.
New York State Department of Health, United States.
Vaccine. 2021 Jul 22;39(32):4404-4406. doi: 10.1016/j.vaccine.2021.06.061. Epub 2021 Jun 25.
Healthcare providers can play a key role in reaching the target for vaccine uptake through educating the public on the risk may be of severe allergic reactions to COVID-19 vaccines. Thus, it is important to resolve reports in the literature which present conflicting data on vaccine safety. We performed a prospective study of Pfizer-BioNTech vaccinations administered at the Albany Community Vaccination Center. All potential vaccinees to the site were screened for allergic history prior to triage by a board-certified allergist. In the first 14 days of operation, our site vaccinated 14,655 individuals, 3.9% of which had a personal history of anaphylaxis. While some vaccine recipients had non-allergic complications, none of the visitors suffered any objective, immediate allergic symptoms. Our findings indicate that specialist-confirmed rates of immediate allergic reaction to mRNA SARS-CoV-2 vaccination are far lower than self-reported rates defined by subjective, unconfirmed symptoms.
医疗服务提供者可以通过向公众宣传接种 COVID-19 疫苗可能出现的严重过敏反应，在实现疫苗接种目标方面发挥关键作用。因此，解决文献中存在的报告疫苗安全性数据相互矛盾的问题很重要。我们对奥尔巴尼社区疫苗接种中心接种辉瑞-生物技术疫苗的情况进行了前瞻性研究。在分诊前，由一名经过董事会认证的过敏症专家对所有潜在的疫苗接种者进行过敏史筛查。在运营的头 14 天里，我们的接种点为 14655 人接种了疫苗，其中 3.9%的人有过敏史。虽然一些疫苗接种者有非过敏并发症，但没有一名访客出现任何客观的、立即的过敏症状。我们的研究结果表明，专家确认的 mRNA SARS-CoV-2 疫苗接种即时过敏反应率远低于主观、未经证实的症状定义的自我报告率。
